United Therapeutics Corporation (UTHR) Return on equity 2016–2025
United Therapeutics Corporation (UTHR) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
18.8%FY2025 · since FY2016: 38.6% → 18.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 18.8% | +0.3 pp |
| FY2024 | 18.5% | +2.1 pp |
| FY2023 | 16.5% | +1.3 pp |
| FY2022 | 15.2% | +3.1 pp |
| FY2021 | 12.0% | -3.1 pp |
| FY2020 | 15.2% | +18.9 pp |
| FY2019 | -3.8% | -24.9 pp |
| FY2018 | 21.1% | +1.2 pp |
| FY2017 | 19.9% | -18.7 pp |
| FY2016 | 38.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More UTHR financial trends
UTHR RevenueUTHR Net incomeUTHR Net marginUTHR Gross profitUTHR Gross marginUTHR Operating incomeUTHR Operating marginUTHR Operating cash flowUTHR Free cash flowUTHR Capital expendituresUTHR Stock buybacksUTHR Dividends paidUTHR Total assetsUTHR Total liabilitiesUTHR Shareholders’ equityUTHR overview →